Felix Biotechnology

Felix Biotechnology is a biotherapeutics company with a focus on microbial challenges in human health. Felix Biotechnology is developing precision phage therapy to manage antibiotic-resistant bacterial infection, using a phage licensed from Yale University and discovery and engineering platforms from University of Califoria Berkeley.

Felix Biotechnology’s technology has been deployed to treat multidrug resistant (MDR) bacteria and pan-drug resistant (PDR) Pseudomonas aeruginosa infections in cystic fibrosis patients using a compassionate use IND. The company also has candidates to target S. aureus, MRSA infections, Burkhholderia and Acinetobacter as well as discovery biotherapeutics targeting certain fungal infections.